The stock of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) last traded at $3.79, up 1.07% from the previous session.
Data from the available sources indicates that Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is covered by 5 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $25.00 and a low of $10.00, we find $16.00. Given the previous closing price of $3.75, this indicates a potential upside of 326.67 percent. MIST stock price is now -10.24% away from the 50-day moving average and -38.79% away from the 200-day moving average. The market capitalization of the company currently stands at $128.59M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
In total, 0 analysts have assigned it a hold rating, and 5 have given it a buy rating. Brokers who have rated the stock have averaged $16.40 as their price target over the next twelve months.
With the price target enhanced from $8 to $10, Piper Sandler Upgraded its rating from Neutral to Overweight for Milestone Pharmaceuticals Inc. (NASDAQ: MIST). On March 05, 2021, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $20, while ‘Oppenheimer’ rates the stock as ‘Outperform’.
In other news, Bharucha David, Chief Medical Officer bought 7,000 shares of the company’s stock on Dec 05. The stock was bought for $32,830 at an average price of $4.69. Upon completion of the transaction, the Chief Medical Officer now directly owns 10,000 shares in the company, valued at $37900.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 01, Chief Medical Officer Bharucha David bought 3,000 shares of the business’s stock. A total of $14,580 was incurred on buying the stock at an average price of $4.86. This leaves the insider owning 3,000 shares of the company worth $11370.0. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MIST stock. A new stake in Milestone Pharmaceuticals Inc. shares was purchased by VR ADVISER, LLC during the first quarter worth $9,194,000. GREAT POINT PARTNERS I LP invested $2,557,000 in shares of MIST during the first quarter. In the first quarter, PARADIGM BIOCAPITAL ADVISORS LP acquired a new stake in Milestone Pharmaceuticals Inc. valued at approximately $2,404,000. CITADEL ADVISORS LLC acquired a new stake in MIST for approximately $2,263,000. JANUS HENDERSON GROUP PLC purchased a new stake in MIST valued at around $2,123,000 in the second quarter. In total, there are 35 active investors with 64.20% ownership of the company’s stock.
With an opening price of $3.7600 on Friday morning, Milestone Pharmaceuticals Inc. (NASDAQ: MIST) set off the trading day. During the past 12 months, Milestone Pharmaceuticals Inc. has had a low of $3.39 and a high of $9.85. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 12.70, and a quick ratio of 12.70. The fifty day moving average price for MIST is $4.2128 and a two-hundred day moving average price translates $6.1754 for the stock.
The latest earnings results from Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.39, missing analysts’ expectations of -$0.36 by -0.03. This compares to -$0.34 EPS in the same period last year.
Milestone Pharmaceuticals Inc.(MIST) Company Profile
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
